about
Identification and characterization of NIF3L1 BP1, a novel cytoplasmic interaction partner of the NIF3L1 proteinMECP2 mutations in sporadic cases of Rett syndrome are almost exclusively of paternal originThe human H2A and H2B histone gene complementIdentification and characterization of a novel murine multigene family containing a PHD-finger-like motifTherapeutic options in post-transplant lymphoproliferative disorders.Acute esophageal necrosis (black esophagus) in the renal transplant recipient: manifestation of primary cytomegalovirus infection.Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study.Fcγ-receptor IIIA polymorphism p.158F has no negative predictive impact on rituximab therapy with and without sequential chemotherapy in CD20-positive posttransplant lymphoproliferative disorder.Interindividual variability of response to rituximab: from biological origins to individualized therapies.Expression profiling of Epstein-Barr virus-encoded microRNAs from paraffin-embedded formalin-fixed primary Epstein-Barr virus-positive B-cell lymphoma samples.A comprehensive analysis of the cellular and EBV-specific microRNAome in primary CNS PTLD identifies different patterns among EBV-associated tumors.The Seville expert workshop for progress in posttransplant lymphoproliferative disorders.A novel GFAP mutation and disseminated white matter lesions: adult Alexander disease?Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.MECP2 gene nucleotide changes and their pathogenicity in males: proceed with caution.Treatment of PTLD with rituximab and CHOP reduces the risk of renal graft impairment after reduction of immunosuppression.Evidence for genetic susceptibility towards development of posttransplant lymphoproliferative disorder in solid organ recipients.BK-VP3 as a new target of cellular immunity in BK virus infection.Targeted expression of SV40 large tumour antigen (TAg) induces a transient enhancement of spermatocyte proliferation and apoptosis.Plasmablastic posttransplant lymphoma: cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome in the prospective German Posttransplant Lymphoproliferative Disorder Registry.TSPY-LTA transgenic mice develop endocrine tumors of the pituitary and adrenal gland.Efficiency of antiviral therapy plus IVIG in a case of primary EBV infection associated PTLD refractory to rituximab, chemotherapy, and antiviral therapy alone.Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD.Early and late posttransplant lymphoproliferative disorder after lung transplantation--34 cases from the European PTLD Network.Impact of high risk thrombophilia status on recurrence among children and adults with VTE: An observational multicenter cohort study.Venous thromboembolism in recurrent ovarian cancer-patients: A systematic evaluation of the North-Eastern German Society of Gynaecologic Oncology Ovarian Cancer Study Group (NOGGO).Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after Upfront chemotherapy: the role of single-agent rituximab.The Caenorhabditis elegans ortholog of human PHF5a shows a muscle-specific expression domain and is essential for C. elegans morphogenetic development.The murine BTB/POZ zinc finger gene Znf131: predominant expression in the developing central nervous system, in adult brain, testis, and thymus.Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an anInternational prognostic index, type of transplant and response to rituximab are key parameters to tailor treatment in adults with CD20-positive B cell PTLD: clues from the PTLD-1 trial.IL-6 and IL-10 in post-transplant lymphoproliferative disorders development and maintenance: a longitudinal study of cytokine plasma levels and T-cell subsets in 38 patients undergoing treatment.Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.[Diagnostic and therapeutic management of patients receiving antithrombotic drugs: what to heed?]Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD).[Standards and perspectives in locoregional hyperthermia].Radioimmunotherapy ((90) Y-Ibritumomab Tiuxetan) for Posttransplant Lymphoproliferative Disorders After Prior Exposure to Rituximab.Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era.Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.Haemorrhage due to proteolysis of FXIII and hyperfibrinolysis under vemurafenib treatment of metastatic melanoma.
P50
Q24319130-31D63FE8-8A01-447E-BBBD-94A2475758C4Q24533455-B0F75AFE-1389-4393-94F9-323781A1937CQ28138093-19545066-28E4-4288-AB85-C930F399BBDAQ28587685-5BA031FE-CD72-453A-81C8-A18B6EF48EEEQ30455714-A7B8B733-D251-4C7D-BC52-8D0785E38C76Q33374318-B60847FC-11AD-454B-AFC9-9EDAADADFEB2Q35080086-C56244B6-E80B-4CF8-A619-FB356CF237F2Q37704588-6F213CA2-BC72-4644-8036-BB591089EA18Q37826285-1D871C5E-CD5B-497F-9D93-6DB3238ED65DQ38403375-61C9365E-6A71-448E-8E0D-E8DBC2FE1173Q38965273-5FF8BE06-7551-48DE-BEC3-04AF7BA2840FQ39550390-96943842-FF86-4851-8F5E-9B07A23514C2Q42446729-5BFACBC3-026C-42FF-82EB-DAA3B7093B09Q42628866-A0513DD8-6131-4DE5-89EA-40E80F243DD2Q43074622-1090DDC9-329A-4840-9DA3-EA6794FB30E1Q43296371-E92BFBA7-C203-453E-8413-998481116E87Q43553267-8DF67B9F-3DB6-44B4-A838-433A996A9027Q43702582-E9738FCB-D578-4DF1-989D-B53C7730FECDQ43806692-21AA90A9-3AD1-4B3E-810B-CE9E77495857Q44172624-18202CCC-8B36-4390-815F-CEC72EB7B11EQ44366987-12DE6299-B952-43A6-8BDB-C4591D96FB11Q44674887-A0DFFC4D-FC33-4002-93DB-A0A7693A9A18Q44968633-F0360255-0540-42AD-B049-1EAF1A72412EQ45132382-8AC7B3E9-4232-4DAB-99FA-076F3D634A1BQ45861806-DA5B57A6-935E-4A7F-B2A3-E239495F5339Q46019608-F163B569-956E-4AE7-A034-1BCC312E6046Q46828168-820EBB3B-AA3F-447D-87BF-6F21C983BA47Q47069552-9DD8952C-78FF-4C60-8A20-8B71E1C22654Q48521357-DC957344-486D-48B3-8B8F-33B1AEC149F4Q48627718-7F1CCC54-640D-4A38-A26F-6AB057E1E245Q49152860-B53D568A-79D8-47AF-8A8E-9AB3B10FFAD0Q52894728-9E9AD91D-2F7C-4FA2-86F6-2EEA34A535BAQ52926389-AEA101E1-9A33-42E5-9B6F-9E717121C3C5Q52933099-26C8B677-3DC9-4D54-BD03-B6CE993512BEQ52935805-057E2358-0047-41BD-BD6E-20D8BCBD6B58Q52944656-CBBBED4B-EA76-415E-9534-27D6D280E7E6Q52951948-7202EB17-5BCF-43B0-A208-83D1D93C9F34Q53109465-D1EF4455-094E-4AF1-B414-2F06C72CAA2DQ53214879-1355CA12-E478-404F-A371-F98302FB528AQ53755915-F5543736-5A85-46C8-81E5-B07CF82764F2
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ralf Trappe
@ast
Ralf Trappe
@en
Ralf Trappe
@es
Ralf Trappe
@nl
Ralf Trappe
@sl
type
label
Ralf Trappe
@ast
Ralf Trappe
@en
Ralf Trappe
@es
Ralf Trappe
@nl
Ralf Trappe
@sl
prefLabel
Ralf Trappe
@ast
Ralf Trappe
@en
Ralf Trappe
@es
Ralf Trappe
@nl
Ralf Trappe
@sl
P1053
E-6048-2012
P106
P108
P21
P31
P3829
P496
0000-0001-7565-7160